David Nierengarten analyst WEDBUSH

Currently out of the existing stock ratings of David Nierengarten, 499 are a BUY (85.3%), 78 are a HOLD (13.33%), 8 are a SELL (1.37%).

David Nierengarten

Work Performance Price Targets & Ratings Chart

Analyst David Nierengarten, currently employed at WEDBUSH, carries an average stock price target met ratio of 43.42% that have a potential upside of 36.83% achieved within 184 days.

David Nierengarten’s has documented 1,214 price targets and ratings displayed on 85 stocks. The coverage is on Healthcare, Communication Services, Technology, Energy, Consumer Cyclical sectors.

Most recent stock forecast was given on STRO, Sutro Biopharma.

Wall Street Analyst David Nierengarten

Analyst best performing recommendations are on ABVX (ABIVAX SA).
The best stock recommendation documented was for ABVX (ABIVAX SA) at 6/2/2026. The price target of $90 was fulfilled within 1 day with a profit of $17.5 (24.14%) receiving and performance score of 241.38.

Average potential price target upside

ANAB AnaptysBio ARAV Aravive ARGX argenx NV ADR AVRO AVROBIO BEAM Beam Therapeutics BLUE Bluebird bio BPMC Blueprint Medicines Corp CDAK Codiak BioSciences COGT Cogent Biosciences EPZM Epizyme FATE Fate Therapeutics GTHX G1 Therapeutics INZY Inozyme Pharma ITOS Iteos Therapeutics KPTI Karyopharm Therapeutics MGNX MacroGenics MYOK MyoKardia NTLA Intellia Therapeutics NUVB Nuvation Bio NVCR Novocure Ltd ORTX Orchard Therapeutics PLC STML Stemline Therapeutics STRO Sutro Biopharma TC TuanChe ADR TCRR Tcr2 Therapeutics TPTX Turning Point Therapeutics TSVT 2Seventy Bio XNCR Xencor YMAB Y mAbs Therapeutics CDTX Cidara Therapeutics KNSA Kiniksa Pharmaceuticals Ltd SRRK Scholar Rock Holding Corp SWTX SpringWorks Therapeutics VYGR Voyager Therapeutics AGTC Applied Genetic ARDX Ardelyx MRUS Merus BV PRTA Prothena plc RARE Ultragenyx KNTE Kinnate Biopharma VOR Vor Biopharma BMRN Biomarin Pharmaceutical MGTA Magenta Therapeutics NFLX Netflix BOLD Audentes Therapeutics FENC Fennec Pharmaceuticals ISEE IVERIC bio NUVL Nuvalent ONCE Spark Therapeutics THRX Theseus Pharmaceuticals CMRX Chimerix MRSN Mersana Therapeutics FRLN Freeline Therapeutics Holdings Plc GBIO Generation Bio Co FUSN Fusion Pharmaceuticals MAXN Maxeon Solar Technologies Ltd ORIC Oric Pharmaceuticals IMNM Immunome TCRX Tscan Therapeutics IKNA Ikena Oncology APGE Apogee Therapeutics BCAX Bicara Therapeutics CATX Perspective Therapeutics IRON Disc Medicine CLDX Celldex Therapeutics ACET Adicet Bio BL Blackline BP BP PLC ADR CM Canadian Imperial Bank Of Commerce EC Ecopetrol SA ADR FR First Industrial Realty Trust IT Gartner KN Knowles Cor MG Mistras Group STM STMicroelectronics NV ADR STTK Shattuck Labs SW Smurfit WestRock plc SY So-Young International THR TLX Telix Pharmaceuticals SYRE Spyre Therapeutics ABVX Abivax SA GT Goodyear Tire & Rubber Co EIGR Eiger Biopharmaceuticals AKTS Akoustis Technologies

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 07-Aug-2024

$60

$13.39 (28.73%)

20 days ago
(30-Sep-2026)

11/13 (84.62%)

$9.74 (19.38%)

385

Buy Since 10-Jun-2026

$95

$48.39 (103.82%)

$95

26 days ago
(24-Sep-2026)

0/3 (0%)

$43.3 (83.75%)

Buy Since 03-Oct-2024

$81

$34.39 (73.78%)

$85

27 days ago
(23-Sep-2026)

3/5 (60%)

$30.23 (59.54%)

135

Buy Since 17-Mar-2026

$76

$29.39 (63.06%)

$60

5 months 7 days ago
(13-May-2026)

3/4 (75%)

$13.31 (21.23%)

47

Buy Since 16-Feb-2024

$93

$29.85 (47.27%)

$95

5 months 16 days ago
(04-May-2026)

0/6 (0%)

$23.22 (33.28%)

Show more analysts

Please expand the browser size to see the chart

Which stock is David Nierengarten most bullish on?

Potential upside of $330.86 has been obtained for ARGX (ARGENX NV ADR)

Which stock is David Nierengarten most reserved on?

Potential downside of -$0.07 has been obtained for APGE (APOGEE THERAPEUTICS)

What Year was the first public recommendation made by David Nierengarten?

On 2011
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?